PACT logo

Find a trial

PACT Update

As with everything during the global COVID-19 pandemic, pulmonary fibrosis clinical trials and PACT activities have been majorly impacted. Thank you to all involved in the (ongoing) clinical response to COVID-19.
PACT is excited to continue supporting important pulmonary fibrosis trials in Australasia as the region returns to business as usual. To stay up to date, become a member.

Become a member long-arrow-right

PACT partnership with HealthMatch to help patients access clinical trials

Finding and accessing clinical trials can be difficult for Pulmonary Fibrosis patients. PACT has partnered with HealthMatch to make this process easier and more efficient. Use the link below to find out more about matching for current and future Pulmonary Fibrosis clinical trials and create a profile.

Visit HealthMatch long-arrow-right

Deciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia.

Recruiting Trials

Trial Title Status More Information
STARSCAPE WA42293 A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis. Recruitment paused – due to reopen June 2022

Trial Summary

Clinicaltrials.gov ID: NCT04552899
GALACTIC-1 A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks. Recruiting

Trial Summary

Clinicaltrials.gov ID: NCT03832946
TELO-SCOPE Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis. Recruiting

Trial Summary

Clinicaltrials.gov ID: NCT04638517
PFOX PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial Recruiting

Trial Summary

Clinicaltrials.gov ID: NCT03737409
HIIT High intensity interval training in fibrotic interstitial lung disease Recruiting

Trial Summary

Clinicaltrials.gov ID: NCT03800914
GRIPF Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF) Recruiting

Trial Summary

Not Applicable
BMS IM027-040 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis. Recruiting; planned to close 10th June 2022

Trial Summary

Not Applicable

Trials Closed to Recruitment

Trial Title Status More Information
BI 1305-0013 Title: A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. Closed to Recruitment Clinicaltrials.gov ID: NCT04419506 

ATLAS AP01-002 A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Closed to Recruitment Clinicaltrials.gov ID: ACTRN12618001838202

Trail1 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD) Closed to recruitment

The TRAIL1 study continued enrolment through the planned timeline, but was somewhat impacted by COVID and did not meet enrolment goals.
Clinicaltrials.gov ID: NCT02808871
AGN120-1 An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough Closed to Recruitment Clinicaltrials.gov ID: NCT04318704

Zephyrus FGCL-3019-091 FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). Closed to recruitment Clinicaltrials.gov ID: NCT03955146

Completed Trials

Trial Title Status More Information
HHF-ILD Handheld fan for breathlessness in interstitial lung disease Study completed Clinicaltrials.gov ID: ACTRN12618001949279
COLDICE Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE Study completed Clinicaltrials.gov ID: ACTRN12615000718549

Discontinued Trials

Trial Title Status More Information
SCENIC Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial Discontinued

The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.

Clinicaltrials.gov ID: NCT03864328

Isabela 1&2 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis Discontinued

The decision to discontinue the ISABELA Phase 3 clinical studies was based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies.

Clinicaltrials.gov ID: NCT0371l-162

Clinicaltrials.gov ID: NCT03733444

Blade Therapeutics A Phase 1a/1b, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Subjects with Lung Fibrosis or Liver Fibrosis Discontinued Clinicaltrials.gov ID: NCT03559166
SPIRIT A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Discontinued ClinicalTrials.gov ID: NCT03573505

PACT is funded by the NHMRC Centre of Research Excellence in Pulmonary Fibrosis and generously supported by: